Introduction Pramipexole, a dopamine D2/D3 receptor agonist initially developed for Parkinson’s disease and restless legs syndrome, has shown emerging utility as an off-label treatment for bipolar depression. Its mechanism—preferential D3 stimulation—targets motivational and reward …